SHR-1701: all 50 studies that test it
Page 1 of 1. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.
- Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingNCT07874425Phase 2
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialRecruitingNCT07847710Phase 2
- Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy FailureNot yet recruitingNCT07817654Phase 2
- Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic CancerNot yet recruitingNCT07814859Phase 2
- Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07802288Phase 2
- GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDACNot yet recruitingNCT07802184Phase 1/2
- Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic CancerNot yet recruitingNCT07773363Phase 2
- An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual ImagingNot yet recruitingNCT07770672Phase 2
- Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast CancerNot yet recruitingNCT07752550Phase 2
- SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaNot yet recruitingNCT07749859Phase 2
- Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07709767Phase 2
- Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric CancerRecruitingNCT07689851Phase 2
- Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver MetastasesNot yet recruitingNCT07677293Phase 3
- Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCCNot yet recruitingNCT07618910Phase 2
- Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction CancerNot yet recruitingNCT07610629Phase 2
- Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLCNot yet recruitingNCT07567326Phase 2
- Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)Not yet recruitingNCT07550920Phase 2
- SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After ImmunotherapyNot yet recruitingNCT07524374Phase 2
- Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal MelanomaNot yet recruitingNCT07517653Phase 2
- Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingNCT07503639Phase 2
- Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and EfficacyNot yet recruitingNCT07493382Not applicable
- Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal CancerRecruitingNCT07478731Phase 2
- A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian CancerNot yet recruitingNCT07355010Phase 2
- SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy FailureRecruitingNCT07311408Phase 2
- Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer SubjectsRecruitingNCT07175220Phase 2
- Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.Not yet recruitingNCT07147088Phase 2
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06893887Not applicable
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular SubtypingNot yet recruitingNCT06881017Phase 2
- SHR-1701 Combined with SHR2554 and BP102 for MCRCNot yet recruitingNCT06679673Phase 2
- SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT05896046Phase 1/2
- Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric CancerRecruitingNCT05671822Phase 2
- To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced MelanomaRecruitingNCT05106023Phase 2
- Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell LymphomasRecruitingNCT04407741Phase 1/2
- Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic CancerActive, not recruitingNCT07806110Phase 2
- Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaActive, not recruitingNCT07682376Phase 2
- SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLCStatus unknownNCT05177497Phase 2
- Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Phase 2/3
- A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-CancerStatus unknownNCT05132413Phase 3
- SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05020925Phase 1/2
- A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung CancerStatus unknownNCT04884009Phase 2
- A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLCWithdrawnNCT04699968Phase 2
- A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid TumorsStatus unknownNCT04679038Phase 1/2
- SHR-1701 in Patients With Recurrent/Metastatic ScchnStatus unknownNCT04650633Phase 2
- A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic CancerCompletedNCT04624217Phase 1/2
- A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLCActive, not recruitingNCT04580498Phase 2
- A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line TreatmentStatus unknownNCT04560244Phase 2
- Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
- A Trial of SHR-1701 in Subjects With Advanced Solid TumorsCompletedNCT04324814Phase 1
- SHR-1701 in Subjects With Metastatic or Locally Advanced Solid TumorsStatus unknownNCT03774979Phase 1
- SHR-1701 in Metastatic or Locally Advanced Solid TumorsStatus unknownNCT03710265Phase 1